Related references
Note: Only part of the references are listed.Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice
Sara A. Healy et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
A human monoclonal antibody blocks malaria transmission and defines a highly conserved neutralizing epitope on gametes
Camila H. Coelho et al.
NATURE COMMUNICATIONS (2021)
Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention
Daniel Chandramohan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention
Daniel Chandramohan et al.
LANCET INFECTIOUS DISEASES (2021)
Comparison of carrier proteins to conjugate malaria transmission blocking vaccine antigens, Pfs25 and Pfs230
Puthupparampil Scaria et al.
VACCINE (2020)
Outer membrane protein complex as a carrier for malaria transmission blocking antigen Pfs230
Puthupparampil Scaria et al.
NPJ VACCINES (2019)
Safety and immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adults
Issaka Sagara et al.
LANCET INFECTIOUS DISEASES (2018)
Adjuvant system AS01: helping to overcome the challenges of modern vaccines
Arnaud M. Didierlaurent et al.
EXPERT REVIEW OF VACCINES (2017)
Strategies & recent development of transmission-blocking vaccines against Plasmodium falciparum
Neha Chaturvedi et al.
INDIAN JOURNAL OF MEDICAL RESEARCH (2016)
Structural and Immunological Characterization of Recombinant 6-Cysteine Domains of the Plasmodium falciparum Sexual Stage Protein Pfs230
Nicholas J. MacDonald et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Safety and Immunogenicityof Pfs25-EPA/Alhydrogel® , a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naive Adults
Kawsar R. Talaat et al.
PLOS ONE (2016)
Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial
H. Tinto et al.
LANCET (2015)
Comparative Assessment of Transmission-Blocking Vaccine Candidates against Plasmodium falciparum
M. C. Kapulu et al.
SCIENTIFIC REPORTS (2015)
Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle
Richard L. Shimp et al.
VACCINE (2013)
A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants
Sara Mian-McCarthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Naturally Acquired Immune Responses to Plasmodium falciparum Sexual Stage Antigens Pfs48/45 and Pfs230 in an Area of Seasonal Transmission
Andre Lin Ouedraogo et al.
INFECTION AND IMMUNITY (2011)
AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity
Arnaud M. Didierlaurent et al.
JOURNAL OF IMMUNOLOGY (2009)
Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51
Yimin Wu et al.
PLOS ONE (2008)
Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A:: A strategy for enhancing immunogenicity of malaria vaccine candidates
Feng Qian et al.
VACCINE (2007)
Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex
Yimin Wu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Malaria transmission-blocking antigen, Pfs230, mediates human red blood cell binding to exflagellating male parasites and oocyst production
Saliha Eksi et al.
MOLECULAR MICROBIOLOGY (2006)
Do malaria ookinete surface proteins P25 and P28 mediate parasite entry into mosquito midgut epithelial cells?
LA Baton et al.
MALARIA JOURNAL (2005)
Pfs230: from malaria transmission-blocking vaccine candidate toward function
KC Williamson
PARASITE IMMUNOLOGY (2003)
P25 and P28 proteins of the malaria ookinete surface have multiple and partially redundant functions
AM Tomas et al.
EMBO JOURNAL (2001)
A region of Plasmodium falciparum antigen Pfs25 that is the target of highly potent transmission-blocking antibodies
AW Stowers et al.
INFECTION AND IMMUNITY (2000)
Share Paper
